Teva Pharmaceutical Industries ADR (TEVA) Stock Price, Quote & News

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 3 914 8213

Website: www.tevapharm.com

Address:

124 Dvora HaNevi’a St., Tel Aviv, Israel

HedgeAlerts Nov. 16 at 10:36 PM

Hedge Alert Live - Protect Your Portfolio Contract: $TEVA $25.00 Put · NOV 21, 2025 Exp Entry Price: $0.29 - $0.32 Exit Price Target: $0.69 Profit Margin: +138% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

clan Nov. 16 at 9:35 PM

$ELTP Longterm trend in share price will remain up ↗️ for Elite Pharma. Production expanding. Pipeline advancing. Revenues and Profits increasing. 💊💲 Wake up $TEVA $SUNPHARMA.NSE

0 · Reply

HedgeAlerts Nov. 15 at 10:39 PM

0 · Reply

LiquidThetaOptions Nov. 15 at 10:27 PM

💎 LiquidTheta® Live Actionable Trade Asset: $TEVA Contracts: $TEVA January 15, 2027 $27 Calls Scale in: $4.04- $4.94 Scale out: $15.71-$26.92 Profit Potential : 120% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Hshshhssos Nov. 15 at 7:20 PM

$TEVA druckenmiller continuing to add to his Teva stake

0 · Reply

bundy3333 Nov. 15 at 3:07 PM

$KODK once upon a time $TEVA and $KODK share prices have been more or less the same Which revenue KODK will have achieved with pharmaceutics during the last three FYs 2022 till 2025 aand and compare this with the market cap, TEVA has gained during that time frame just to remind some people here pumping KODK since then while dumping TEVA since then SR RmSJJoCompare

0 · Reply

Champi2305 Nov. 15 at 3:05 PM

$TEVA $OCS cash till 2029. Do you know a biotech company with such a financial horizon ? With a succeed stage 2 trial and results within 6 months for the stage 3 ? And Pionner trials launched and financed ! It's almost unique.

0 · Reply

Lund06 Nov. 15 at 6:18 AM

$TEVA great analysis - have been invested in Teva for years and really happy to see the progression last years

1 · Reply

roblake29 Nov. 15 at 4:22 AM

$TEVA In case anyone is interest in my independent (non shareholder) analysis of Teva: https://seekingalpha.com/article/4843855-generics-stalwart-teva-has-turned-a-corner-in-its-specialty-medicines-business

0 · Reply

LiquidThetaOptions Nov. 14 at 10:09 PM

💎 LiquidTheta® Live Actionable Trade Asset: $TEVA Contracts: $TEVA January 15, 2027 $27 Calls Scale in: $4.03- $4.92 Scale out: $15.66-$26.85 Profit Potential : 148% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business

Nov 10, 2025, 2:51 PM EST - 6 days ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 6:00 PM EST - 9 days ago

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Nov 5, 2025, 1:02 PM EST - 11 days ago

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Nov 5, 2025, 1:01 PM EST - 11 days ago

Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 11:30 AM EST - 11 days ago

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook

Nov 5, 2025, 9:14 AM EST - 11 days ago

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Nov 5, 2025, 7:44 AM EST - 11 days ago

Teva Pharm third-quarter profit tops estimates as branded drugs gain

Nov 5, 2025, 7:00 AM EST - 11 days ago

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Oct 31, 2025, 4:30 PM EDT - 16 days ago

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Oct 30, 2025, 11:45 AM EDT - 17 days ago

Blood pressure medicine recalled over high levels of cancer-causing chemical

Oct 20, 2025, 4:30 PM EDT - 27 days ago

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Oct 17, 2025, 12:18 PM EDT - 4 weeks ago

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

VTRS

Oct 10, 2025, 3:00 PM EDT - 5 weeks ago

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Oct 7, 2025, 4:07 AM EDT - 5 weeks ago

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside

Sep 25, 2025, 4:30 PM EDT - 7 weeks ago

Teva Releases Q3 2025 Aide Memoire

Sep 25, 2025, 4:30 PM EDT - 7 weeks ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sep 25, 2025, 11:42 AM EDT - 7 weeks ago

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors

Sep 24, 2025, 7:23 AM EDT - 7 weeks ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 22, 2025, 2:53 PM EDT - 7 weeks ago

Teva Pharmaceutical Industries Limited - Special Call

Sep 20, 2025, 10:15 PM EDT - 2 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Sep 17, 2025, 8:00 AM EDT - 2 months ago

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Sep 16, 2025, 4:30 PM EDT - 2 months ago

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Sep 9, 2025, 12:57 PM EDT - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 5, 2025, 3:57 PM EDT - 2 months ago

Colorado must face Teva's lawsuit over free allergy pen law

Sep 2, 2025, 4:30 PM EDT - 2 months ago

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Aug 28, 2025, 9:17 AM EDT - 2 months ago

US FDA approves Teva Pharmaceuticals' generic obesity drug

Aug 28, 2025, 1:43 AM EDT - 2 months ago

Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue

Aug 19, 2025, 9:00 AM EDT - 3 months ago

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

Aug 5, 2025, 6:16 PM EDT - 3 months ago

US FDA approves Teva's Ajovy for migraine prevention in children

Jul 31, 2025, 3:27 PM EDT - 3 months ago

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

Jul 30, 2025, 12:40 PM EDT - 3 months ago

Teva CEO: Our supply chain puts us in a strong position

Jul 30, 2025, 11:50 AM EDT - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:21 AM EDT - 3 months ago

Teva Pharm Q2 profit beats estimates as branded drugs gain

Jul 29, 2025, 2:44 PM EDT - 3 months ago

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Jun 26, 2025, 4:30 PM EDT - 5 months ago

Teva Releases Q2 2025 Aide Memoire

Jun 25, 2025, 4:30 PM EDT - 5 months ago

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Jun 23, 2025, 3:00 AM EDT - 5 months ago

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Jun 16, 2025, 9:03 AM EDT - 5 months ago

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Jun 10, 2025, 11:46 AM EDT - 5 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 5, 2025, 7:09 AM EDT - 5 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript

Jun 3, 2025, 5:30 PM EDT - 5 months ago

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Jun 3, 2025, 7:16 AM EDT - 5 months ago

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

May 30, 2025, 9:05 PM EDT - 6 months ago

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

May 30, 2025, 9:00 PM EDT - 6 months ago

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

May 29, 2025, 8:00 AM EDT - 6 months ago

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

May 27, 2025, 5:30 PM EDT - 6 months ago

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

May 27, 2025, 4:30 PM EDT - 6 months ago

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

May 27, 2025, 3:44 PM EDT - 6 months ago

Why Is Teva Stock Trading Higher On Tuesday?

May 27, 2025, 8:30 AM EDT - 6 months ago

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

HedgeAlerts Nov. 16 at 10:36 PM

0 · Reply

clan Nov. 16 at 9:35 PM

$ELTP Longterm trend in share price will remain up ↗️ for Elite Pharma. Production expanding. Pipeline advancing. Revenues and Profits increasing. 💊💲 Wake up $TEVA $SUNPHARMA.NSE

0 · Reply

HedgeAlerts Nov. 15 at 10:39 PM

0 · Reply

LiquidThetaOptions Nov. 15 at 10:27 PM

0 · Reply

Hshshhssos Nov. 15 at 7:20 PM

$TEVA druckenmiller continuing to add to his Teva stake

0 · Reply

bundy3333 Nov. 15 at 3:07 PM

0 · Reply

Champi2305 Nov. 15 at 3:05 PM

0 · Reply

Lund06 Nov. 15 at 6:18 AM

$TEVA great analysis - have been invested in Teva for years and really happy to see the progression last years

1 · Reply

roblake29 Nov. 15 at 4:22 AM

0 · Reply

LiquidThetaOptions Nov. 14 at 10:09 PM

0 · Reply

TheDudeRooster Nov. 14 at 9:03 PM

$TEVA Wow…writes weren’t having it. All that 26.0 and 25.5 money in the toilet. A lot of push money thrown away in the last 2 days.

2 · Reply

HedgeAlerts Nov. 14 at 6:22 PM

Hedge Alert Live - Protect Your Portfolio Contract: $TEVA $25.00 Put · NOV 21, 2025 Exp Entry Price: $0.34 - $0.37 Exit Price Target: $0.74 Profit Margin: +101% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

LakersandVRX Nov. 14 at 4:30 PM

$TEVA you know the board here is quiet bc things are not happening as expected. Wanting to tell all of us “I told you so”.

0 · Reply

shepsale Nov. 14 at 4:19 PM

$TEVA

0 · Reply

GetOverHere_ Nov. 14 at 8:50 AM

$ATAI $VUZI $STRK.X $TEVA ~

0 · Reply

HedgeAlerts Nov. 14 at 7:42 AM

Hedge Alert Live - Protect Your Portfolio Contract: $TEVA $25.00 Put · NOV 21, 2025 Exp Entry Price: $0.34 - $0.38 Exit Price Target: $0.61 Profit Margin: +79% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

TheDudeRooster Nov. 13 at 9:07 PM

$TEVA You know they gotta maintain the 25.5 strike tomorrow to avoid the splat. Should have never pushed for that 26.0 and just allowed it to consolidate.

0 · Reply

TheDudeRooster Nov. 13 at 7:08 PM

$TEVA They grabbed my stop. Watch it rip now 😂

0 · Reply

tkstockpicker Nov. 13 at 6:06 PM

$TEVA trimmed more on oversized position for 50% gain on that lot

0 · Reply

Gemineye Nov. 13 at 5:51 PM

$TEVA one day?????

0 · Reply

LakersandVRX Nov. 13 at 5:46 PM

$TEVA Even the great Michael Burry can't predict markets. Yes, I read the Big Short. Made him look like some genius market predictor that dropped out of med school. CNBC listens to everything he says. Now his Scion Capital is no more. He got lucky making billions on credit default swaps....lucky.

1 · Reply

TheDudeRooster Nov. 13 at 5:32 PM

$TEVA $25.80 & $26.50 stops in. I will raise the $26.50 if the ITM options continue to fabricate the squeeze in the float.

0 · Reply

Market Cap	29.14B
Revenue (ttm)	16.54B
Net Income (ttm)	-1.64B
EPS (ttm)	N/A
PE Ratio	9.90
Forward PE	10.18
Profit Margin	-9.91%
Debt to Equity Ratio	2.31

Volume	10,222,300
Avg Vol	11,512,248
Day's Range	N/A - N/A
Shares Out	1.15B
Stochastic %K	85%
Beta	0.70
Analysts	Strong Sell
Price Target	$27.75